Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10367665 | 1.00 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| Bromide SCHEMBL735632 | 0.97 | HRH3 (0.57) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL2099368 | 0.97 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL10368003 | 0.97 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| Hydrochloric Acid SCHEMBL21486302 | 0.95 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| SCHEMBL1944808 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL17106615 | 0.92 | HRH3 (0.57) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| Bromide SCHEMBL22664299 | 0.90 | HRH3 (0.71) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| Bromide SCHEMBL28639845 | 0.90 | HRH3 (0.71) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT | |
| Bromide SCHEMBL4670073 | 0.90 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294545-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117126159-A | Water-soluble evodiamine derivative and application thereof | 南华大学附属第一医院 | 2023-11-28 | — | — | CN | disclosed |
| EP-4219499-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-08-02 | — | — | EP | disclosed |
| CN-116322699-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| CN-105820107-B | Prodrug of non-steroidal anti-inflammatory drug with rapid skin and biological membrane penetration speed and novel medical application thereof | 泰飞尔公司 | 2022-09-09 | — | — | CN | disclosed |
| EP-3619200-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | AXXAM S.p.A. (IT) | 2020-03-11 | — | — | EP | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| CN-110770214-A | Heterocyclic P2X7 antagonists | 阿克萨姆股份公司 | 2020-02-07 | — | — | CN | disclosed |
| EP-1944301-A1 | NOVEL BENZOXATHIIN DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-16 | — | — | EP | disclosed |
| EP-1892241-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1757594-A1 | QUINAZOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-1717230-A1 | FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-02 | — | — | EP | disclosed |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-0090972-B1 | INDAZOLE DERIVATIVES | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1990-05-30 | — | — | EP | disclosed |
| US-4751302-A | ANTIINFLAMMATORY, ANTIULCER AGENTS, ANALGESICS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1988-06-14 | — | — | US | disclosed |
| US-4533731-A | ANTIINFLAMMATORY AGENTS | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1985-08-06 | — | — | US | disclosed |
| EP-0090972-A2 | Indazole derivatives | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-10-12 | — | — | EP | disclosed |
| US-4022788-A | HYPERTENSIVE AGENT, SOFTENERS | E. R. SQUIBB & SONS, INC. (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | P2RY1, P2RX1, P2RX3 | SIGMAR1 138/4885HRH3 20/4885CYP1A2 783/4885 |
| US-20240294545-A1 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | ATM, CHEK2, CHEK1 | SIGMAR1 4860/4885HRH3 2978/4885CYP1A2 3252/4885 |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | SIGMAR1 138/4885HRH3 20/4885CYP1A2 783/4885 |
| US-20050182045-A1 | Fused ring 4-oxopyrimidine derivative | HRH4, HRH2, HRH3 | SIGMAR1 129/4885HRH3 3/4885CYP1A2 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.